Carol Heller will be working with Jeff Bernstein to cover the state of Pennsylvania as local group leaders. She is very excited to help and hold meetings, and will be handling the eastern region of [...]
The new treatment uses T cells, a type of immune cell that are taken from the patient’s body, genetically modified and then reinfused into the patient. These modified T cells are called chimeric antigen receptor (CAR) T cells. In previous trials with these modified T cells, tumor responses have been modest and they did not persist for long enough after being re-introduced into the patient. Using this second generation CAR T cell, Dr. Carl June and his colleagues at Penn obtained long-lasting persistence once the cells were re-introduced.
How does a $2 million-a-year cancer research effort with a team of nine scientists keep pace with a $100 million-a-year project with a team of 200? Pretty well, it turns out. With the Cancer Genome Atlas project in the news lately—the New York Times recently reported on progress in its colon cancer work—we decided to compare some of its data with that of the Life Raft Group’s Research Team and its D-Day Project. Our research focuses on GIST.
Two posters were presented by principal investigators in the Phase 2 and 3 trials of masitinib for the treatment of newly diagnosed GIST patients.
Since he turned 14, Jasper Smit of the Netherlands has been searching for patients like him. This is very difficult because Carney’s Triad is an extremely rare syndrome. Worldwide there are about 30 known patients with a ‘complete’ Carney’s Triad (GISTs, pulmonary chondromas, paragangliomas). Incomplete Carney’s Triad affects less than 100 patients in the world. This means that they have two of the three types of tumor (mostly GISTs and pulmonary chondromas). In his own words, here is Jasper’s story.
I was caught up in a whirlwind when I found out that I had cancer on a Monday morning in October of 2011. I was admitted to the hospital that same day in preparation to have emergency surgery the next morning to remove the tumors and then found out I had GIST - all in a 24 hour period! I felt like my world had turned upside down and shortly after that during my recovery, I was lucky enough to find Life Raft.
About 80 GIST patients, relatives, GIST experts, interested professionals, physicians and representatives of the pharmaceutical industry gathered at the Restaurant Au Premier at Zurich Main Station in Zurich on April 8 for the ninth meeting of the Swiss GIST group. A warm welcome was extended to special guests Candy Heberlein, President of the Swiss Foundation for the Promotion of Bone Marrow Transplantation, and Christel Jäger-Freysoldt, chief executive of Das Lebenshaus in Germany.
Executive Director Norman Scherzer talks about the founding of the Life Raft Group and the importance of Gleevec in the fight against GIST (Gastrointestinal Stromal Tumor).
Twelve years ago, Life Rafter Bobby Kinsey began his own battle against GIST. Since then, he has helped countless people with GIST across the world. Most of you know Bobby as an LRG member who posts advice and words of encouragement in our email community. Now, Bobby has decided that he wants to do more to help fight this cancer.
The Life Raft Group wishes to thank all of our members who participated in this year’s Holiday Campaign. Though it is still underway (look for final results in the next newsletter), this important campaign has raised over $47,000 to support our patient education & support, advocacy, and research to find a cure GIST.
